{"jsonapi":{"version":"1.0"},"data":{"type":"recalls","id":"544ecc5f0a74c9eb62ddfd3ac2beec41cc2f5560fa030f25805e9380b05619dd","attributes":{"feedName":"fda","feedSource":"fda","title":"Takeda Issues US Recall of NATPARA® (parathyroid hormone) for Injection Due to the Potential for Rubber Particulate","description":"Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the company is issuing a US recall for all doses of NATPARA® (parathyroid hormone) for Injection (25 mcg, 50 mcg, 75 mcg, and 100 mcg). This recall is being conducted after discussions with the FDA and is effec","link":"https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/takeda-issues-us-recall-natparar-parathyroid-hormone-injection-due-potential-rubber-particulate","publicationDate":"2019-09-16T03:05:12.000Z","state":"sent","affected":[],"allergens":[],"audience":["professionals"],"categories":["drugs"],"contaminants":["foreign"],"distribution":["AK","AL","AR","AZ","CA","CO","CT","DC","DE","FL","GA","HI","IA","ID","IL","IN","KS","KY","LA","MA","MD","ME","MI","MN","MO","MS","MT","NC","ND","NE","NH","NJ","NM","NV","NY","OH","OK","OR","PA","RI","SC","SD","TN","TX","UT","VA","VT","WA","WI","WV","WY"],"risk":"possible","token":"5d9e69028b079e002a252437"}}}